The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC
Videos  >  

Results for First-Line Pembrolizumab in Advanced Urothelial Carcinoma

Arjun Balar, MD
Published Online:7:50 PM, Wed June 21, 2017

Arjun Balar, MD, assistant professor, Department of Medicine, and director, Genitourinary Medical Oncology Program, NYU Langone Medical Center, discusses biomarker findings and mature clinical results from KEYNOTE-052, which explored first-line pembrolizumab (Keytruda) in cisplatin-ineligible advanced urothelial carcinoma. 
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.